New IPF pill enters mid-stage trial – could it slow lung decline?
NCT ID NCT05060822
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental tablet called HEC585 in 270 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. Participants receive either HEC585, a placebo (dummy pill), or an active comparator (Pirfenidone) to see if HEC585 can improve lung function over 24 weeks. The goal is to find the right dose that slows disease progression with acceptable side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care